{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:48:09Z","timestamp":1790380089183,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Human papillomavirus (HPV) vaccines represent an important strategic opportunity to prevent cervical cancer in low\u2010middle income countries, such as India. The economic evaluation of HPV vaccines is crucial to inform public\u2010health decisions; however, the scarce economic evaluations from India have focused on the value for money of bivalent vaccines and took a healthcare perspective. The aim of this study is to conduct a cost\u2010effectiveness analysis of all available HPV vaccines in India.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used to evaluate the cost\u2010effectiveness of HPV vaccination of 12\u2010year\u2010old girls in India, from both healthcare and societal perspectives. Cervical cancer cases, deaths averted and the incremental cost per Disability Adjusted Life Years (DALY) averted were reported as primary outcomes. Sensitivity analysis was undertaken to handle any uncertainty or variability in the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with no vaccination, the incremental cost per DALY averted was USD 362.78 for nonavalent vaccine, USD 393.16 for quadrivalent vaccine and USD 432.24 for bivalent vaccine from a healthcare perspective. From a societal perspective, the incremental cost per DALY averted was USD 334.28 for nonavalent vaccine, USD 364.67 for quadrivalent vaccine and USD 403.75 for bivalent vaccine. Assuming constant prices per dose for all vaccines, the nonavalent vaccine dominated both quadrivalent and bivalent vaccines, indicating that it is the more cost\u2010effective strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vaccinating girls against HPV is a cost\u2010effective strategy to reduce the incidence of cervical cancer and mortality due to cervical cancer in India.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13962","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:08:16Z","timestamp":1683112096000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost\u2010effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India"],"prefix":"10.1111","volume":"20","author":[{"given":"Shiksha","family":"Arora","sequence":"first","affiliation":[{"name":"The Centre for the Business and Economics of Health The University of Queensland, Brisbane  Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[{"name":"The Centre for the Business and Economics of Health The University of Queensland, Brisbane  Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_3_1","unstructured":"National Technical Advisory Group on Immunization.Minutes of the meeting of the National Technical Advisory Group on Immunization (NTAGI).2017."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.25259\/IJMS_140_2020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(02)00188-0"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.115"},{"issue":"3","key":"e_1_2_10_8_1","first-page":"637","article-title":"Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (Review)","volume":"52","author":"Boda D","year":"2018","journal-title":"Int J Oncol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600688"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1559827615569707"},{"key":"e_1_2_10_11_1","unstructured":"World Health Organization.Global strategy to accelerate the elimination of cervical cancer as a public health problem.Geneva: World Health Organization; 2020."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238291"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604462"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-8080(08)32409-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30734"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"e_1_2_10_18_1","unstructured":"World Health Organization.WHO guide for standardization of economic evaluations of immunization programmes. World Health Organization;2019."},{"key":"e_1_2_10_19_1","unstructured":"World Health Organization.Global Health Observatory data repository 2019. Available from:https:\/\/apps.who.int\/gho\/data\/view.main.60740?lang=en"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60946-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"e_1_2_10_23_1","volume-title":"India National Family Health Survey NFHS\u20104 2015\u201316","author":"International Institute for Population Sciences \u2010 IIPS\/India","year":"2017"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.07.012"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00954-y"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.9.2639"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2297-x"},{"key":"e_1_2_10_28_1","unstructured":"CCEMG\u2010EPPI\u2010Centre cost converterAvailable from:http:\/\/eppi.ioe.ac.uk\/costconversion\/Defaultaspx"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30068-4"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.013"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.037"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106836"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00576-7"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.004"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/01411920701434102"},{"key":"e_1_2_10_36_1","unstructured":"Serum Institute of India Pvt. Ltd. PRODUCT PIPELINE 2020Available from:https:\/\/www.seruminstitute.com\/product_pipeline.php"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30022-X"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.09.003"},{"key":"e_1_2_10_39_1","unstructured":"The World Bank. GDP per capita (current US$)Available from:https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10849-y"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv282"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003006"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:17:02Z","timestamp":1711646222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/ajco.13962"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13962","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"2021-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}